Nowadays, cancer has become the second highest leading cause of death, and it is expected to continue to affect the population in forthcoming years. Additionally, treatment options will become less accessible to the public as cases continue to grow and disease mechanisms expand. Hence, specific candidates with confirmed anticancer effects are required to develop new drugs. Among the novel therapeutic options, proteins are considered a relevant source, given that they have bioactive peptides encrypted within their sequences. These bioactive peptides, which are molecules consisting of 2–50 amino acids, have specific activities when administered, producing anticancer effects. Current databases report the effects of peptides. However, uncertainty is found when their molecular mechanisms are investigated. Furthermore, analyses addressing their interaction networks or their directly implicated mechanisms are needed to elucidate their effects on cancer cells entirely. Therefore, relevant peptides considered as candidates for cancer therapeutics with specific sequences and known anticancer mechanisms were accurately reviewed. Likewise, those features which turn certain peptides into candidates and the mechanisms by which peptides mediate tumor cell death were highlighted. This information will make robust the knowledge of these candidate peptides with recognized mechanisms and enhance their non-toxic capacity in relation to healthy cells and further avoid cell resistance.

中文翻译：

---

天然肽诱导癌细胞死亡：癌症治疗特定候选物的机制和性质

如今，癌症已成为第二大死因，预计在未来几年将继续影响人口。此外，随着病例的不断增加和疾病机制的扩大，公众可以获得的治疗选择将变得越来越少。因此，需要具有确定的抗癌作用的特定候选药物来开发新药。在新的治疗选择中，蛋白质被认为是相关的来源，因为它们的序列内具有加密的生物活性肽。这些生物活性肽是由 2-50 个氨基酸组成的分子，在给药时具有特定的活性，产生抗癌作用。当前的数据库报告了肽的影响。然而，在研究它们的分子机制时会发现不确定性。此外，需要对它们的相互作用网络或其直接相关的机制进行分析，以完全阐明它们对癌细胞的影响。因此，准确地审查了被认为具有特定序列和已知抗癌机制的癌症治疗候选物的相关肽。同样，突出显示了将某些肽转化为候选肽的那些特征以及肽介导肿瘤细胞死亡的机制。这些信息将使这些候选肽具有公认的机制的强大知识，并增强它们与健康细胞相关的无毒能力，并进一步避免细胞耐药性。准确审查了被认为具有特定序列和已知抗癌机制的癌症治疗候选物的相关肽。同样，突出显示了将某些肽转化为候选肽的那些特征以及肽介导肿瘤细胞死亡的机制。这些信息将使这些候选肽具有公认的机制的强大知识，并增强它们与健康细胞相关的无毒能力，并进一步避免细胞耐药性。准确审查了被认为具有特定序列和已知抗癌机制的癌症治疗候选物的相关肽。同样，突出显示了将某些肽转化为候选肽的那些特征以及肽介导肿瘤细胞死亡的机制。这些信息将使这些候选肽具有公认的机制的强大知识，并增强它们与健康细胞相关的无毒能力，并进一步避免细胞耐药性。